Avicena is a private company backed by the Australian government. Our mission is to develop low-cost ultra-high-throughput molecular diagnostic and screening instruments to detect SARS-CoV-2 and other pathogens. Learning from the experience of the global pandemic, our platform is designed for pandemic-scale throughput. Avicena's Sentinel systems can screen more than 100,000 individuals with saliva samples every 24 hours.